Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Carles

Showing results (121-130 of 139) with videos related to

Pageof 14
Sort By:
Journal of Hepatology|June 14, 2000
Increased incidence of HFE C282Y mutations in patients with iron overload and hepatocellular carcinoma developed in non-cirrhotic liverJ F Blanc, V De Ledinghen, P H Bernard, et al.
Rheumatology International|March 12, 2014
Bone mass behavior after 1 year of different treatment strategies in prostate cancer patients subjected to androgen deprivation therapyJ Planas Morin, A Celma Domenech, J Placer Santos, et al.
Histology and Histopathology|November 13, 2013
Schwannomas, benign tumors with a senescent phenotypeS Simonetti, C Serrano, J Hernández-Losa, et al.
Medicina Intensiva|July 14, 2020
Clinical risk factors for early mortality in patients with community-acquired septic shock. The importance of adequate source controlJ Vallés, E Diaz, J Carles Oliva, et al.
British Journal of Cancer|March 5, 2002
Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancerX Garcia del Muro, E Marcuello, J Gumá, et al.
British Journal of Cancer|October 24, 2007
Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II studyJ Carles, A Font, B Mellado, et al.
Emerging Infectious Diseases|April 18, 2018
Human Usutu Virus Infection with Atypical Neurologic Presentation, Montpellier, France, 2016Yannick Simonin, Olivier Sillam, Marie J Carles, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 24, 2011
Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activityJ Bellmunt, J L González-Larriba, C Prior, et al.
Actas Urologicas Espanolas|February 21, 1998
[Early diagnosis by opportunistic screening in cancer of the prostate. Results of a 1-year protocol. Comparison with historical data]A Gelabert Mas, O Arango Toro, J Carles Galcerán, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 19, 2007
Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapyJ Bellmunt, L Paz-Ares, M Cuello, et al.
Pageof 14

Showing results (121-130 of 139) with videos related to

Sort By:
Pageof 14
Journal of Hepatology|June 14, 2000
Increased incidence of HFE C282Y mutations in patients with iron overload and hepatocellular carcinoma developed in non-cirrhotic liverJ F Blanc, V De Ledinghen, P H Bernard, et al.
Rheumatology International|March 12, 2014
Bone mass behavior after 1 year of different treatment strategies in prostate cancer patients subjected to androgen deprivation therapyJ Planas Morin, A Celma Domenech, J Placer Santos, et al.
Histology and Histopathology|November 13, 2013
Schwannomas, benign tumors with a senescent phenotypeS Simonetti, C Serrano, J Hernández-Losa, et al.
Medicina Intensiva|July 14, 2020
Clinical risk factors for early mortality in patients with community-acquired septic shock. The importance of adequate source controlJ Vallés, E Diaz, J Carles Oliva, et al.
British Journal of Cancer|March 5, 2002
Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancerX Garcia del Muro, E Marcuello, J Gumá, et al.
British Journal of Cancer|October 24, 2007
Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II studyJ Carles, A Font, B Mellado, et al.
Emerging Infectious Diseases|April 18, 2018
Human Usutu Virus Infection with Atypical Neurologic Presentation, Montpellier, France, 2016Yannick Simonin, Olivier Sillam, Marie J Carles, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 24, 2011
Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activityJ Bellmunt, J L González-Larriba, C Prior, et al.
Actas Urologicas Espanolas|February 21, 1998
[Early diagnosis by opportunistic screening in cancer of the prostate. Results of a 1-year protocol. Comparison with historical data]A Gelabert Mas, O Arango Toro, J Carles Galcerán, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 19, 2007
Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapyJ Bellmunt, L Paz-Ares, M Cuello, et al.
Pageof 14